Swiss pharmaceutical company Roche's hostile $3bn offer for an American healthcare company has hit a major snag in the form of a local law as concerns rise about US markets becoming inhospitable to foreigners.

Last month Roche bid $3bn for Tuscon, Arizona-based Ventana Medical, a maker of cancer diagnostic systems, in a deal that would be a 55% premium to the target's three-month average stock price.